{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:36:29Z","timestamp":1777480589554,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2022,5,13]]},"abstract":"<jats:p>BACKGROUND: Although Abelson (ABL) tyrosine kinase inhibitors (TKIs) have demonstrated potency against chronic myeloid leukemia (CML), resistance to ABL TKIs can develop in CML patients after discontinuation of therapy. OBJECTIVE: Glucose metabolism may be altered in CML cells because glucose is a key metabolite used by tumor cells. We investigated whether D-mannose treatment induced metabolic changes in CML cells and reduced CML growth in the presence of ABL TKIs. METHODS: We investigated whether D-mannose treatment induced metabolic changes in CML cells and reduced CML growth in the presence of ABL TKIs. RESULTS: Treatment with D-mannose for 72\u00a0h inhibited the growth of K562 cells. Combined treatment using ABL TKIs and D-mannose induced a significantly higher level of cytotoxicity in Philadelphia chromosome (Ph)-positive leukemia cells than in control cells. In the mouse model, severe toxicity was observed as evidenced by body weight loss in the ponatinib and D-mannose combination treatment groups. CONCLUSION: Our results indicate that metabolic reprogramming may be a useful strategy against Ph-positive leukemia cells. However, caution should be exercised during clinical applications.<\/jats:p>","DOI":"10.3233\/cbm-210141","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T11:25:14Z","timestamp":1641295514000},"page":"337-346","source":"Crossref","is-referenced-by-count":4,"title":["Effect of D-mannose on Philadelphia chromosome-positive leukemia cells"],"prefix":"10.1177","volume":"34","author":[{"given":"Seiichi","family":"Okabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"5405","key":"10.3233\/CBM-210141_ref1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"12","key":"10.3233\/CBM-210141_ref2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.3233\/CBM-210141_ref3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.3233\/CBM-210141_ref4","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective bcr-abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"19","key":"10.3233\/CBM-210141_ref5","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.3233\/CBM-210141_ref6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5\u20136","key":"10.3233\/CBM-210141_ref7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1515\/bmc-2015-0018","article-title":"Adaptive regulation of glucose transport, glycolysis and respiration for cell proliferation","volume":"6","author":"Toyoda","year":"2015","journal-title":"Biomol Concepts"},{"key":"10.3233\/CBM-210141_ref8","doi-asserted-by":"crossref","first-page":"12:152","DOI":"10.1186\/1476-4598-12-152","article-title":"Tumor glycolysis as a target for cancer therapy: progress and prospects","volume":"12","author":"Ganapathy-Kanniappan","year":"2013","journal-title":"Mol Cancer"},{"key":"10.3233\/CBM-210141_ref9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","article-title":"Aerobic glycolysis: meeting the metabolic requirements of cell proliferation","volume":"27","author":"Lunt","year":"2011","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"7733","key":"10.3233\/CBM-210141_ref10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41586-018-0729-3","article-title":"Mannose impairs tumour growth and enhances chemotherapy","volume":"563","author":"Gonzalez","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.3233\/CBM-210141_ref11","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual bcr-abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.3233\/CBM-210141_ref12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10911-013-9310-8","article-title":"Biology of glucose transport in the mammary gland","volume":"19","author":"Zhao","year":"2014","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"2","key":"10.3233\/CBM-210141_ref13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.3233\/CBM-210141_ref14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2337\/db08-0080","article-title":"Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db\/db mice","volume":"58","author":"Han","year":"2009","journal-title":"Diabetes"},{"issue":"10","key":"10.3233\/CBM-210141_ref15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2174\/138161212799504902","article-title":"Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis","volume":"18","author":"Dhup","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"5\u20136","key":"10.3233\/CBM-210141_ref16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1023\/A:1022069718709","article-title":"What determines the intracellular ATP concentration","volume":"22","author":"Ataullakhanov","year":"2002","journal-title":"Biosci Rep"},{"issue":"23","key":"10.3233\/CBM-210141_ref17","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.1113\/JP273839","article-title":"Oxidative phosphorylation: regulation and role in cellular and tissue metabolism","volume":"593","author":"Wilson","year":"2017","journal-title":"J Physiol"},{"issue":"2","key":"10.3233\/CBM-210141_ref18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbrc.2014.06.021","article-title":"Mannose metabolism: more than meets the eye","volume":"453","author":"Sharma","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/CBM-210141_ref19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front Oncol"},{"issue":"12","key":"10.3233\/CBM-210141_ref20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41585-018-0106-x","article-title":"Nonantibiotic prevention and management of recurrent urinary tract infection","volume":"15","author":"Sihra","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"22","key":"10.3233\/CBM-210141_ref21","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.3233\/CBM-210141_ref22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/cam4.1920","article-title":"Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and bcr-abl inhibitor use by using an adverse drug event reporting database","volume":"8","author":"Okada","year":"2019","journal-title":"Cancer Med"},{"issue":"65","key":"10.3233\/CBM-210141_ref23","doi-asserted-by":"crossref","first-page":"32496","DOI":"10.18632\/oncotarget.25985","article-title":"Therapeutic targeting of aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells","volume":"9","author":"Okabe","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.3233\/CBM-210141_ref24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00280-019-04022-x","article-title":"Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells","volume":"85","author":"Okabe","year":"2020","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-210141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:08:39Z","timestamp":1777385319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/CBM-210141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":24,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/cbm-210141","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,13]]}}}